TrialJournal of bone and mineral metabolism2020

Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.

Junichi Takada et al.PubMed ↗Publisher ↗

No numbers read from the abstract.